CClinicalTrials.gg
CompletedNCT02529631Updated Aug 20, 2015

RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

An interventional study of orlistat 60 mg and polyglucosamine in Overweight and Obesity, sponsored by Certmedica International GmbH. Completed at 2 sites in 2 countries. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-20.

Sponsored by Certmedica International GmbH · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

This trial compares two treatment methods:

  1. Orlistat 60 mg to be taken three times daily one capsule; indicated for weight loss in overweight adults. Important is also that it is taken along with a reduced-calorie and low-fat diet.
  2. Polyglucosamine tablets to be taken two times daily two tablets, taken with the two main meals with the highest fat content, indicated for weight maintenance and weight loss.
02

Conditions studied

  • Overweight
  • Obesity

Keywords

  • Polyglucosamine
  • L 112
  • overweight,
  • obesity
  • orlistat
  • weight reduction
03

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI ≥ 28 kg/m² and \< 45 kg/m²
  • Waist circumference > 80 cm (women) > 94 cm (men)

Exclusion criteria

Exclusion Criteria:

  • Energy intake lower than the standard value according to Miffin St-Jeor equation
  • Pregnancy or breast-feeding
  • Addiction to alcohol
  • Inability to fulfil the requirement of the trial protocol
  • Cancer ,malignant tumour
  • Hypersensitivity reactions to crustaceans or ingredient of the study medication
  • Chronic diseases not under control with adequate therapy
  • Diabetes
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Drug: orlistat 60mg capsules

    A tailored blister-strip for one day contains * three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with * six placebo tablets Administration: 3 times daily 2 tablets with each main meal

    Drug: orlistat 60 mg

  • Active comparator
    Medical device: polyglucosamine

    A tailored blister-strip for one day contains * three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with * six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold "breakfast" are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine

    Device: polyglucosamine

Interventions

  • Drugorlistat 60 mg

    In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity. Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets.

  • Devicepolyglucosamine

    In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity. Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening).

05

What researchers measure

Primary outcomes

  1. Number of participants in both groups with a weight reduction of >= 5 per cent compared to the initial weight.

    Time frame: 12 weeks

Secondary outcomes

  1. BMI reduction

    Achieved change of the BMI (cm/m²) of all participants in each group compared to the initial average BMI

    Time frame: 12 weeks

  2. Waist circumference reduction

    Achieved change of the waist circumference of all participants in each group compared to the initial average WC

    Time frame: 12 weeks

06

Study locations

2 sites
  • Diabetological Center
    Dreieich, Hesse 63303, Germany
  • MAP Center
    Rende, Cosenza 87036, Italy
07

References and documents

Publications

  • Stoll M, Bitterlich N, Cornelli U. Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity. BMC Obes. 2017 Jan 11;4:4. doi: 10.1186/s40608-016-0130-4. eCollection 2017. PubMed 28097013 ↗
08

Registry details

Key details

Study ID
NCT02529631
Lead sponsor
Certmedica International GmbH
Responsible party
Sponsor
First posted
Aug 20, 2015
Start date
Nov 2009
Primary completion
Jun 2010
Completion
Aug 2013
Last update
Aug 20, 2015

Study contacts

Manfred Stoll, MD
principal investigator · Diabetological centre, Dreieich, Germany
Umberto Cornelli, MD
principal investigator · CorCon, Mailand, Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion